Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5578544 | Journal of Pain and Symptom Management | 2016 | 30 Pages |
Abstract
This trial failed to show any difference in tolerability and analgesic efficacy of morphine and oxycodone as first-line treatment for moderate/severe cancer pain but results interpretation is difficult due to lack of power, potential bias from open-label design, and concerns about assay sensitivity. These data, however, can significantly contribute to future meta-analyses comparing WHO Step-III opioids and are relevant in designing future randomized studies.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Ernesto MD, Cinzia MSc, Paola MD, Giuseppe MD, Carlo MD, Roberto MD, Luigi MD, Marco MD, Cecilia MD, Ugo MD, Gabriele MD, Maria Teresa MD, Vittorio MD, Oscar MD, Giovanni MD, Stein MD, Augusto MD,